Registration Is Now Open For Tribe Public's Webinar Event "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity" Featuring Modular Medical CEO On Wednesday, September 11, 2024
Modular Medical (Nasdaq: MODD) has announced a webinar event titled 'Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity' featuring CEO Jeb Besser. The event, scheduled for September 11, 2024, will address critical health issues and market opportunities. Key points include:
- Over 3 million people in the US use daily insulin for diabetes management
- Only 20% of insulin-dependent patients currently use insulin pumps
- Obesity is linked to 30-53% of new diabetes cases annually in the US
- About 50% of patients prescribed GLP-1 drugs for weight loss discontinue within 12 weeks
The webinar aims to discuss these trends and Modular Medical's potential in the insulin pump technology market.
Modular Medical (Nasdaq: MODD) ha annunciato un evento webinar intitolato 'Diabete, Obesità, GLP-1, e L'Opportunità MODD-1' con il CEO Jeb Besser. L'evento, programmato per il 11 settembre 2024, affronterà questioni sanitarie cruciali e opportunità di mercato. I punti chiave includono:
- Oltre 3 milioni di persone negli Stati Uniti utilizzano insulina quotidianamente per la gestione del diabete
- Solo il 20% dei pazienti che dipendono dall'insulina utilizza attualmente pompe per insulina
- L'obesità è correlata al 30-53% dei nuovi casi di diabete ogni anno negli Stati Uniti
- Circa il 50% dei pazienti a cui sono prescritti farmaci GLP-1 per la perdita di peso interrompe il trattamento entro 12 settimane
Il webinar si propone di discutere queste tendenze e il potenziale di Modular Medical nel mercato della tecnologia delle pompe per insulina.
Modular Medical (Nasdaq: MODD) ha anunciado un evento webinar titulado 'Diabetes, Obesidad, GLP-1 y La Oportunidad MODD-1' con el CEO Jeb Besser. El evento, programado para el 11 de septiembre de 2024, abordará cuestiones de salud críticas y oportunidades de mercado. Los puntos clave incluyen:
- Más de 3 millones de personas en EE. UU. utilizan insulina diariamente para el manejo de la diabetes
- Solo el 20% de los pacientes dependientes de insulina utiliza actualmente bombas de insulina
- La obesidad está relacionada con el 30-53% de los nuevos casos de diabetes anuales en EE. UU.
- Alrededor del 50% de los pacientes a quienes se les recetan medicamentos GLP-1 para la pérdida de peso interrumpen el tratamiento dentro de las 12 semanas
El webinar tiene como objetivo discutir estas tendencias y el potencial de Modular Medical en el mercado de la tecnología de bombas de insulina.
모듈러 메디컬(Modular Medical, Nasdaq: MODD)이 CEO 제브 베서(Jeb Besser)가 참석하는 웨비나 이벤트 '당뇨병, 비만, GLP-1 및 MODD-1 기회'를 발표했습니다. 이 이벤트는 2024년 9월 11일에 예정되어 있으며, 중요한 건강 문제와 시장 기회를 다룰 것입니다. 주요 사항은 다음과 같습니다:
- 미국에서 300만 명 이상의 사람들이 당뇨병 관리를 위해 매일 인슐린을 사용합니다
- 현재 인슐린 의존 환자의 20%만이 인슐린 펌프를 사용하고 있습니다
- 비만은 미국에서 매년 새로운 당뇨병 사례의 30-53%와 관련되어 있습니다
- 체중 감량을 위해 GLP-1 약물을 처방받은 환자의 약 50%가 12주 이내에 치료를 중단합니다
이번 웨비나는 이러한 경향과 인슐린 펌프 기술 시장에서 모듈러 메디컬의 잠재력에 대해 논의하는 것을 목표로 합니다.
Modular Medical (Nasdaq: MODD) a annoncé un événement webinar intitulé 'Diabète, Obésité, GLP-1 et L'Opportunité MODD-1' avec le PDG Jeb Besser. L'événement, prévu pour le 11 septembre 2024, abordera des questions de santé cruciales et des opportunités de marché. Les points clés incluent :
- Plus de 3 millions de personnes aux États-Unis utilisent quotidiennement de l'insuline pour gérer le diabète
- Seulement 20% des patients dépendants à l'insuline utilisent actuellement des pompes à insuline
- L'obésité est liée à 30-53% des nouveaux cas de diabète chaque année aux États-Unis
- Environ 50% des patients prescrits des médicaments GLP-1 pour la perte de poids interrompent leur traitement dans les 12 semaines
Le webinar a pour objectif de discuter de ces tendances et du potentiel de Modular Medical sur le marché de la technologie des pompes à insuline.
Modular Medical (Nasdaq: MODD) hat eine Webinar-Veranstaltung mit dem Titel 'Diabetes, Fettleibigkeit, GLP-1 und die MODD-1 Gelegenheit' mit CEO Jeb Besser angekündigt. Die Veranstaltung, die für den 11. September 2024 geplant ist, wird sich mit wichtigen Gesundheitsfragen und Marktchancen befassen. Wichtige Punkte umfassen:
- Über 3 Millionen Menschen in den USA verwenden täglich Insulin zur Diabetes-Management
- Nur 20% der insulinabhängigen Patienten nutzen derzeit Insulinpumpen
- Fettleibigkeit ist mit 30-53% der jährlich in den USA neuen Diabetesfälle verbunden
- Etwa 50% der Patienten, denen GLP-1-Medikamente zur Gewichtsreduktion verschrieben werden, brechen die Behandlung innerhalb von 12 Wochen ab
Das Webinar zielt darauf ab, diese Trends und das Potenzial von Modular Medical im Markt für Insulinpumpentechnologie zu diskutieren.
- Modular Medical is addressing a large market with over 3 million daily insulin users in the US
- Low insulin pump adoption rate (20%) suggests significant growth potential for MODD's technology
- Webinar event may increase investor awareness and interest in MODD stock
- High discontinuation rate of GLP-1 drugs may indicate challenges in long-term treatment adherence
- Competitive market with established players in insulin pump technology
Meet with Modular Medical CEO, Jeb Besser
There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.
100% of patient population require daily insulin injection. Only20% currently use an insulin pump.Obesity is linked to
30% to53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart AssociationAbout half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately
30% discontinuing in the first four weeks
SAN DIEGO, CA / ACCESSWIRE / September 9, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity." The event is scheduled to begin at 8:30am pacific/11:30am eastern on Wednesday, September 11, 2024. To register to join the complimentary event, please visit the Tribe Public LLC at MODD-GLP-1.TribePublic.com.
Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.
About Modular Medical
Modular Medical, Inc. (Nasdaq: MODD) is a medical device company that will launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and clinical efficacy, thereby making top quality insulin delivery both affordable and simple to learn. The Company's mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond "superusers" and providing diabetes care for the rest of us.
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding MODD, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
ABOUT TRIBE PUBLIC LLC
Tribe Public LLC is a San Francisco, CA based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe's complimentary events focus on issues that the Tribe members care about with an emphasis on hosting management teams from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress and plans. Tribe members primarily include Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe members are encouraged to express their interest in speakers they care about and want to learn from at the Tribe Public website via the Tribe's FREE "Wish List" process. Visit Tribe Public's Website to learn more: http://www.tribepublic.com/
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
View the original press release on accesswire.com
FAQ
When is Modular Medical's (MODD) webinar event scheduled?
What is the title of Modular Medical's (MODD) upcoming webinar?
What percentage of insulin-dependent patients currently use insulin pumps, according to Modular Medical (MODD)?
How many people in the US use daily insulin for diabetes management, as mentioned in Modular Medical's (MODD) press release?
